Uveal Melanoma and Melanoma Immunotherapy
Immunocore Limited supports clinical research in advanced uveal melanoma and previously treated non-ocular advanced melanoma, with a clear emphasis on T-cell receptor-based immunotherapy and immune checkpoint combinations.
- HLA-A*0201-restricted treatment approaches
- Overall survival in advanced melanoma
- Combination immunotherapy strategies
The sponsor’s oncology portfolio is centered on treatment approaches for advanced melanoma populations with limited therapeutic options, including patients with metastatic disease and those requiring systemic immune-based therapy.
PRAME-Positive Cancers
The company is also active in advanced PRAME positive cancers, reflecting interest in tumor-associated antigen targeting across difficult-to-treat solid tumors.
- Antigen-directed oncology
- Solid tumor immunotherapy
- Advanced cancer settings
This research area aligns with therapies designed to recognize cancer-specific targets and expand treatment options for patients with advanced malignancies.
Chronic HIV Infection
Immunocore Limited funds studies in virologically suppressed chronic HIV infection, with interest in immune-based strategies for people receiving antiretroviral therapy.
- HIV immunotherapy
- Antiretroviral therapy–treated populations
- Virologic suppression
This area reflects exploration of novel immune interventions in chronic viral disease, with attention to safety and tolerability in treated participants.
Targeted Immune Engineering
Across its portfolio, the sponsor focuses on engineered immune therapies that engage T-cell receptor biology and antigen-specific recognition in both oncology and infectious disease.
- Engineered T-cell therapies
- Antigen-specific immune targeting
- Translational immunology
These programs span solid tumors and chronic viral infection, highlighting a sustained interest in precision immune targeting.
